Rituximab for the treatment of CD20-positive peripheral T-cell lymphoma, unspecified.
Hirata
Yuji
Y
Yokote
Taiji
T
Kobayashi
Kichinosuke
K
Nakayama
Shoko
S
Miyoshi
Takuji
T
Akioka
Toshikazu
T
Hara
Satoshi
S
Tsuji
Motomu
M
Takubo
Takayuki
T
Hanafusa
Toshiaki
T
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab